SCHEMBL3884243

SCHEMBL3884243

Cc1cc(C)c(-c2nc(N3CCOCC3)nc(N3CCN(c4ccccn4)CC3)n2)cc1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 4/20 0.54
MTOR P42345 4/20 0.54
PIK3R1 P27986 3/20 0.54
HPGD P15428 6/20 0.50
KDM4E B2RXH2 5/20 0.50
HSD17B10 Q99714 4/20 0.50
MAPT P10636 4/20 0.50
LMNA P02545 2/20 0.50
TSHR P16473 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
TP53 P04637 1/20 0.50
ALDH1A1 P00352 5/20 0.48
KMT2A Q03164 2/20 0.45
HTT P42858 2/20 0.45
POLB P06746 1/20 0.44
GBA1 P04062 1/20 0.43
NPSR1 Q6W5P4 2/20 0.43
HRH4 Q9H3N8 1/20 0.43
GAA P10253 1/20 0.43
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3887124 0.89 HPGD (0.50) PIK3CAMTORPIK3R1HPGDKDM4E
SCHEMBL3878604 0.88 ALDH1A1 (0.52) PIK3CAMTORPIK3R1HPGDKDM4E
SCHEMBL3879980 0.87 CNR2 (0.51) PIK3CAMTORPIK3R1HPGDKDM4E
SCHEMBL3878071 0.87 LRRK2 (0.51) PIK3CAMTORPIK3R1HPGDKDM4E
SCHEMBL3884202 0.87 PIK3CA (0.50) PIK3CAMTORPIK3R1HPGDKDM4E
SCHEMBL3877480 0.85 PIK3CA (0.51) PIK3CAMTORPIK3R1HPGDKDM4E
SCHEMBL3879447 0.82 HSD17B10 (0.54) PIK3CAMTORPIK3R1HPGDKDM4E
SCHEMBL3878768 0.82 HPGD (0.47) PIK3CAMTORPIK3R1HPGDKDM4E
SCHEMBL1124002 0.81 HPGD (0.60) PIK3CAMTORHPGDKDM4EHSD17B10
SCHEMBL1123454 0.81 HPGD (0.60) PIK3CAMTORHPGDKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US claimed
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-7566712-B2 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION (US) 2009-07-28 US disclosed
US-20070027155-A1 Biaryl piperazinyl-pyridine analogues NEUROGEN CORPORATION 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027155-A1 Biaryl piperazinyl-pyridine analogues GPR174, GPR68, PPARG PIK3CA 1107/4885MTOR 2949/4885PIK3R1 1228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.